US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.88

+0.19150.49%

Volume:49.35K

Turnover:1.92M

Market Cap:354.60M

PE:- -

High:38.94

Open:38.78

Low:38.66

Close:38.69

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:0.65

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars

Benzinga_recent_news

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

World's First CAR-T Therapy for Solid Tumors Available in China Soon

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Press Release: Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Press Release: TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Press Release: NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

Press Release: Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Competition Intensifies in Second-Line EGFR 20ins NSCLC Treatment: Can Fumeitinib Challenge Sunvozertinib's Dominance?

Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Press Release: InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit

Press Release: BeyondSpring Reports 2025 Year-End Financial Results

Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)

Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

Press Release: Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/ORR/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.8815,"timestamp":1787601600000,"preClose":38.69,"halted":0,"volume":49353,"delay":0,"changeRate":0.0049495993796848,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Pre-Mkt","change":0.1915,"latestTime":"08-25 04:37:00 EDT","open":38.78,"high":38.935,"low":38.66,"amount":1915913.762742,"amplitude":0.007108,"askPrice":42.31,"askSize":100,"bidPrice":34.3,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":38.8815,"sharesOutstanding":12900000,"nav":38.62,"aum":352214400,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.85,"preClose":38.8815,"latestTime":"19:30 EDT","volume":11,"amount":427.8905,"timestamp":1787614207188,"change":-0.0315,"changeRate":-0.00081,"amplitude":0},"volumeRatio":0.6500590086906198,"impliedVol":0.1458,"impliedVolPercentile":0.538},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6500590086906198,"shares":9120000,"dividePrice":0,"high":38.935,"amplitude":0.007108,"preClose":38.69,"low":38.66,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.8815,"eps":0,"divideRate":0,"volume":49353,"delay":0,"ttmEps":0,"open":38.78,"prevYearClose":34.16,"prevWeekClose":38.69,"prevMonthClose":38.79,"prevQuarterClose":36.32,"fiveDayClose":38.09,"twentyDayClose":37.26,"sixtyDayClose":36.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629877995","title":"Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629877995","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629877995?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:00","pubTimestamp":1776718800,"startTime":"0","endTime":"0","summary":"SHANGHAI, April  20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3277510/0/en/Junshi-Biosciences-Presents-Results-from-JS207-PD-1-VEGF-BsAb-Phase-2-Combo-Studies-and-JS212-EGFR-HER3-ADC-FIH-Phase-1-2-Study-at-AACR-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","LU2413666426.HKD","BK1504","BK4023","ORR","LU1721428933.USD","CDX","BK4213","LU1093756168.USD","BK4588","LU1169589451.USD","LU2413666699.HKD","BK4121","LU2211817866.USD","BK1508","BK4533","LU1093756325.SGD","BK4548","BK4195","BK4006","BK4231","BK4585","LU0347712357.USD","MTD","IE00BFXG0V08.USD","PD","IND","HCC","IE00B5TLWC47.USD","SD","IE00BYQQ9H92.USD","BK4567","BK1167","LU1169590202.USD","PFS","BK4080","ADC","PR","02038"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627931287","title":"PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627931287","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627931287?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:45","pubTimestamp":1776257100,"startTime":"0","endTime":"0","summary":"78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% Tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274455/37149/en/PDS-Biotech-Announces-Publication-of-Positive-PDS01ADC-Interim-Phase-2-Clinical-Trial-Data-from-Stage-1-of-NCI-led-Metastatic-Colorectal-Cancer-mCRC-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1584","01336","LU0264606111.USD","BK1550","BK4202","BK4581","BK4585","BK4211","ORR","MSS","BK4092","BK4113","LU0572940350.SGD","BK4588","NCI","BK4231","SSI","XBI","LU0572939691.SGD","BK4195","BK1184","ADC","PFS","BK4080","PDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627555674","title":"Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2627555674","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627555674?lang=en_us&edition=fundamental","pubTime":"2026-04-13 21:00","pubTimestamp":1776085200,"startTime":"0","endTime":"0","summary":"The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall response rate  of 99%. WOBURN, Mass., April 13, 2026 /PRNewswire/ --Sirtex Medical , a leading manufacturer of interventional oncology and embolization solutions, today announced landmark 12-month results from the DOORwaY90 study, the first pivotal, prospective, multicenter U.S. trial of Y-90 selective internal radiation therapy  using partition dosimetry in patients with unresectable hepatocellular carcinoma .The DOORwaY90 study met its prespecified co-primary endpoints, demonstrating a 90% complete response  rate and a best overall response rate  of 99%, as assessed by blinded independent central review. All evaluable patients responded to treatment, resulting in 100% local tumor control—one of the highest reported response outcomes in Y-90 therapy. Responses were durable, with 75% lasting beyond six months and a median duration of 295 days, reinforcing the potential of SIR-Spheres Y-90 resin micr","market":"sh","thumbnail":"https://mma.prnewswire.com/media/926923/Sirtex_Medical_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/926923/Sirtex_Medical_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/sirtex-medicals-doorway90-study-demonstrates-100-local-tumor-control-with-sir-spheres-setting-a-new-benchmark-in-y-90-for-hcc-302739680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","USA","CR","SIR","ORR.AU","BK4161","BK7095","ORR","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627430977","title":"IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars","url":"https://stock-news.laohu8.com/highlight/detail?id=2627430977","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627430977?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:48","pubTimestamp":1776080880,"startTime":"0","endTime":"0","summary":"IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanoma; NDA filing planned for 2026.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/13/Eye-In-Close-Up-With-Light-Blue-Iris-Det.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/13/Eye-In-Close-Up-With-Light-Blue-Iris-Det.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/04/51775855/ideaya-eye-cancer-trial-data-beats-standard-therapy-stock-soars","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/04/51775855/ideaya-eye-cancer-trial-data-beats-standard-therapy-stock-soars","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SMP","BK4124","BK4150","BK4195","BK4211","SMA","RSI","BK4217","BK4139","ORR","IDYA","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215188","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215188","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626215188?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:34","pubTimestamp":1775723640,"startTime":"0","endTime":"0","summary":"NANJING, China, April  09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270693/0/en/Leads-Biolabs-Opamtistomig-PD-L1-4-1BB-Bispecific-Antibody-Advances-to-Expansion-Phase-in-First-Line-Biliary-Tract-Cancer-Following-Positive-Safety-and-Preliminary-Efficacy-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","LU2092937221.SGD","OC","PD","ORR","LU2106854487.HKD","LU1917777945.USD","LU2023250504.SGD","BK4023","LU1974910355.USD","LU1169589451.USD","LU2041044095.USD","HCC","LU2360108059.USD","LU2298321311.HKD","IE00BGHQF417.EUR","ODD","LU2023250843.SGD","BK4086","IE0009354923.USD","IE00B2PGVK34.USD","LU1169590202.USD","IE00B3CCJ633.GBP","LU2048586759.USD","BTC","LU0868494617.USD","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626905589","title":"World's First CAR-T Therapy for Solid Tumors Available in China Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2626905589","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626905589?lang=en_us&edition=fundamental","pubTime":"2026-04-09 13:36","pubTimestamp":1775712960,"startTime":"0","endTime":"0","summary":"A New Hope for Patients with Advanced Gastric and Pancreatic Cancers. SHANGHAI, April 9, 2026 /PRNewswire/ -- A groundbreaking new CAR-T cell therapy for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer treatment. Jiahui International Cancer Center will be among the leading medical institutions offering access to this innovative therapy for eligible patients.The therapy, known as satri-cel , is the world's first CAR-T treatment specifically developed for solid tumors targeting Claudin18.2, a biomarker commonly found in gastric  and pancreatic cancers.CAR-T therapy is a highly personalized treatment that uses a patient's own immune cells, reprogrammed to recognize and attack cancer cells with precision. Unlike traditional therapies, CAR-T cells can expand inside the body and continue to fight cancer over time.While CAR-T has already transformed outcomes in blood cancers, this new therapy represen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/worlds-first-car-t-therapy-for-solid-tumors-available-in-china-soon-302737791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","ORR","BK4022","BK7095","BK4230","ORR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505856","title":"Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505856","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505856?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:00","pubTimestamp":1775127600,"startTime":"0","endTime":"0","summary":"Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement ov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/02/3267222/0/en/Updated-Data-from-Phase-1b-2-Study-of-Muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-in-Late-line-Patients-with-Microsatellite-Stable-Colorectal-Cancer-Demonstrate-Improved-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU0266512127.USD","BK4213","ORR","BK4139","BK4211","LU0456854461.SGD","PFS","MSS","BK4113","BK4195","CRC","OS","ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624954487","title":"Press Release: Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624954487","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624954487?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:00","pubTimestamp":1775077200,"startTime":"0","endTime":"0","summary":"In 2025, muzastotug showed 29% confirmed overall response rate  among 21 patients with MSS CRC in the 20 mg/kg dose cohorts. Median overall survival  for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months. 4% overall discontinuation rate, no dose limiting toxicities, and no Grade 4 or 5 treatment-related adverse events  across 67 patients in all dose cohorts supports improved tolerability profile of muzastotug. Randomized Phase 2 trial enrollment ahead of plan, with potential updates in 2026 and results expected in 1H 2027; registration trial expected to begin once optimal dose regimen has been established. Cash and cash equivalents of $74.5 million as of December 31, 2025, plus proceeds raised from the ATM Offering in 2026 year-to-date, anticipated to provide cash runway into early 2028. SAN DIEGO, Calif. and SUZHOU, China, April 01, 2026  -- Adagene Inc.  , a platform-driven, clinical-stage biotechnology company transforming the discovery and development of ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","HCC","BK4097","ADAG","R","OS","BK4232","BK4006","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624518970","title":"Press Release: TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624518970","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624518970?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:45","pubTimestamp":1775043900,"startTime":"0","endTime":"0","summary":"TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's fourth quarter and full year ended December 31, 2025, and provided a corporate update.Dr. Bianco continued, \"We are grateful to have the unwavering support of our shareholders, who are committed to supporting our programs and realizing the potentially meaningful opportunity each one addresses.\". -- Initiated a randomized Phase 3 Accelerated Approval Trial for IFx-2.0 in. first line treatment of patients with advanced or metastatic Merkel Cell. Phase 3 study trial being conducted under a Special Protocol Assessment.  agreement with U.S. Food and Drug Administration . Primary. endpoint of Overall Response Rate  qualifies for accelerated. approval process. Key secondary endpoint of Progression Free Survival.  may satisfy the requirement for a post confirmator","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LU2125154935.USD","LU1116320901.HKD","SG9999002224.SGD","LU2361045086.USD","LU0058720904.USD","LU1974910355.USD","ORR","IE00B4R5TH58.HKD","LU1066051225.USD","LU0203347892.USD","LU1934455194.USD","IE00BBT3K403.USD","LU0266013472.USD","LU2360032135.SGD","IE00B1BXHZ80.USD","IE00BSNM7G36.USD","LU2361044865.SGD","LU0477156953.USD","R","LU0417517546.SGD","SG9999015341.SGD","LU1037948897.HKD","LU2125154778.USD","LU0130102774.USD","LU0868494617.USD","LU1061106388.HKD","LU1929549753.HKD","BK4533","IE00B2B36J28.USD","SG9999014542.SGD","BK4231","BK4585","LU1057294990.SGD","LU1430594728.SGD","LU0985320562.USD","HURA","IE00BN8TJ469.HKD","LU2023250843.SGD","LU0098860793.USD","LU1941712348.USD","LU0965509101.SGD","SGXZ57979304.SGD","LU0208291251.USD","LU1066051811.HKD","PFS","SG9999002232.USD","ADC","IR","MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537732","title":"Press Release: NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537732","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537732?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:15","pubTimestamp":1774988100,"startTime":"0","endTime":"0","summary":"-- Global development program for JNJ-1900  proceeded as planned,building toward opportunity to address one of the largest untapped. markets in oncology through lead programs in head and neck cancer and. -- Clinical results reported across multiple tumor types including. esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and. across solid tumors treated with radiotherapy next to the completion of. -- Strengthened financial position through the closing of a non-dilutive. royalty financing with HealthCare Royalty for up to $71 million and an. -- Advanced the Curadigm Nanoprimer platform with four new patent. applications filed, new in vivo data presentations, external. collaboration momentum building, and the launch of Chemistry,Manufacturing, and Controls  activities to support both internal. -- Cash runway extended into early 2028 with EUR52.8 million in cash and. -- Clinical data readouts expected in 2026 from Phase 1 and 2 studies in. NSCLC , pancreatic cancer, mel","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3PB1722.GBP","LU1066051225.USD","LU0795875086.SGD","LU1074936037.SGD","LU0787776722.HKD","NBTX","LU0345769128.USD","IE00BJJMRZ35.SGD","LU0345770308.USD","LU2237443978.SGD","BK4568","LU2592432038.USD","IE00BFXG1179.USD","LU0267386448.USD","LU1363072403.SGD","LU1066051811.HKD","LU2430703095.HKD","IE00B42XCP33.USD","JNJ","IE00BKVL7J92.USD","LU0149725797.USD","LU1732800096.USD","LU0114720955.EUR","LU2430703251.USD","LU0426412945.USD","CMC","BK4588","LU0320765646.SGD","LU2237443465.HKD","IE00BVYPNW00.USD","LU0070217475.USD","BK4534","LU1280957306.USD","IE00BFTCPJ56.SGD","LU2505996681.GBP","LU0289739699.SGD","LU0882574139.USD","LU1032955483.USD","LU1196500208.SGD","ORR","LU0882574055.USD","BK4504","BK4533","LU2471134523.USD","IE0034235303.USD","LU0098860793.USD","LU0203347892.USD","IE00B1BXHZ80.USD","IE00B2B36J28.USD","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345052","title":"Press Release: Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345052","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345052?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:54","pubTimestamp":1774878840,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced its financial results for the year ended December 31, 2025.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: \"2025 marked a pivotal year for Harbour BioMed as we entered the third phase of our strategic evolution, with a clear roadmap toward our 2028 vision of becoming a global leading platform-based biopharmaceutical group.The Company's strategy is powered by three integrated growth engines. These include building a global leading AI-driven antibody discovery 'new infrastructure' through Nona Biosciences, expanding global partnerships through platform-based collaborations with multinational pharmaceutical companies, and unlocking the global value of its mid- to late-stage pipeline in immunology,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","TSLP","MSS","BK4022","BK4205","BK4590","02142","NEN","BK1161","BK4232","ORR","BK4213","HCC","BK1583","BK1574","LU0266512127.USD","OS","BK4233","BK4006","BK4113","CRC","LU0456854461.SGD","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622237908","title":"Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2622237908","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622237908?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:00","pubTimestamp":1774609200,"startTime":"0","endTime":"0","summary":"AUCATZYL (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL UK launch underway following successful Nat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3263674/0/en/Autolus-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","BK4023","ORR","CRS","NICE","LU0963586101.USD","IE00BFMHRM44.USD","BK4588","ASH","ALL","BK4022","LU2065731478.USD","BK4007","IE0031619046.USD","BK4139","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4539","LENZ","BK4187","BK4533","LU1699723380.USD","BK4006","BK4585","BK4110","IE00B7SZL793.SGD","LU0985320562.USD","BK4566","LU2463526074.USD","BK4109","BK4107","LU2355687059.USD","ACR","CAR","LU1571399168.USD","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103719113","title":"Competition Intensifies in Second-Line EGFR 20ins NSCLC Treatment: Can Fumeitinib Challenge Sunvozertinib's Dominance?","url":"https://stock-news.laohu8.com/highlight/detail?id=1103719113","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103719113?lang=en_us&edition=fundamental","pubTime":"2026-03-27 16:00","pubTimestamp":1774598456,"startTime":"0","endTime":"0","summary":"The recommendation levels in the CSCO (Chinese Society of Clinical Oncology) guidelines serve as a bridge connecting high-level medical evidence with complex clinical decisions. These levels are not...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","ORR","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622247863","title":"Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2622247863","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622247863?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:32","pubTimestamp":1774531920,"startTime":"0","endTime":"0","summary":"-- The global, multicenter Phase I/II clinical trial of CS2009. Australia and China, and the Phase II IND application has been approved. in the US. CS2009 demonstrates an excellent safety profile with a >=Grade. 3 TRAE rate of 23%, along with broad-spectrum anti-tumor activity.Notably, monotherapy data in lung cancer are encouraging: in first-line. NSCLC patients with PD-L1 TPS >=50%, the ORR reached 90% with a DCR of. 100%, while the ORR was 25% in IO-pretreated NSCLC .Furthermore, significant benefits were observed in patients with heavily. pre-treated \"cold tumors,\" achieving an ORR of 40% in non-clear cell. renal cell carcinoma  and 33.3% in soft tissue sarcoma .-- The global Phase Ib multicenter trial of CS5001  is being. advanced rapidly and efficiently in Australia and China, with its R&D. progress ranking among the top two globally. In combination with R-CHOP. rate exceeds 90%, and the ORR reaches 100%. Additionally, the combination. complementing its successful NRDL renewal at","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK1574","BK1161","BK4567","LU1093756325.SGD","BK4006","MTD","LU0210528500.USD","LU0456854461.SGD","BK4022","LU1093756168.USD","LU1169589451.USD","LU2487616109.SGD","BK4533","CC","ORR","BK4023","PD","PK","LU0266512127.USD","LU1721428933.USD","IE00BYQQ9H92.USD","BK4548","PROC","BK4107","BK4181","BK4218","LU0347712357.USD","R","LU2413666426.HKD","LU2211817866.USD","BK4121","LU1169590202.USD","LU2413666699.HKD","02616","CRC","HCC","IE00BFXG0V08.USD","LU0053666078.USD","BK4585","BK4213","BK4156","BK4588","BK4098","BK4232","L","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852318","title":"Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852318","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852318?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"200g Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin CancerPHILADELPHIA, March  26, 2026 (GLOBE NEWSWI","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262893/0/en/Medicus-Pharma-Business-Update-Call-to-Highlight-80-Overall-Response-Rate-ORR-in-Phase-2-SkinJect-Study-and-Agentic-AI-enabled-Drug-Development-Plan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNA","BK4215","BK4139","BCC","LU1169589451.USD","CHAT","BK4213","AGIX","PR","BK4161","CR","BK4023","ORR","LU1169590202.USD","MDCX","BK4567","PD","AIPO","BK4104","CSR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622368079","title":"Press Release: InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2622368079","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622368079?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:04","pubTimestamp":1774443840,"startTime":"0","endTime":"0","summary":"BEIJING, March 25, 2026  -- InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results for 2025 as of December 13, 2025.2025 marked InnoCare's 10th anniversary and a milestone year of transformative growth and strategic execution. The Company achieved its first full year profitability, secured two new drug application  approvals, enhanced market penetration of its core products, accelerated globalization, and made breakthroughs across multiple pipelines. With numerous \"China First\" achievements, InnoCare continues to accelerate its 2.0 development strategy, demonstrating its strong ability to translate scientific innovations into sustainable long-term growth.-- Revenue grew 135.3% year-on-year to RMB 2,375 million1 in 2025, mainly. driven by robust commercial growth and two strategic business development. -- Profit reached RMB 644 million, achieving profitability for the first. time, mainly due to significant com","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1032955483.USD","LU0823417653.USD","LU1235294995.USD","LU2506952170.USD","LU2237443465.HKD","SG9999015978.USD","ORR","LU2237443978.SGD","LU2286300806.USD","BK4579","LU0792757196.USD","CSCL","LU1244550577.SGD","LU1585245621.USD","LU2102340556.USD","LU0320765646.SGD","LU2237443895.HKD","CSCS","BK4533","BK4020","LU0234570918.USD","SG9999015986.USD","LU1066051225.USD","LU1571399168.USD","IE00BGHQF631.EUR","LU1674673428.USD","IE000M9KFDE8.USD","BK4588","LU0203345920.USD","LU1221951046.USD","IE00BVYPNW00.USD","LU1929549753.HKD","CSCO","LU1894683348.USD","LU1599440770.SGD","IE00B42XCP33.USD","IE00BSNM7G36.USD","LU1059921491.USD","LU1066051498.USD","LU1894683264.USD","LU1883839398.USD","BK4585","SG9999015945.SGD","BK4525","LU0234572021.USD","IE00BVYPNV92.GBP","SG9999001424.SGD","TLS","LU1880398471.USD","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622107545","title":"Press Release: BeyondSpring Reports 2025 Year-End Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622107545","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622107545?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:30","pubTimestamp":1774441800,"startTime":"0","endTime":"0","summary":"-- Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors. progressed after first line therapy -- DUBLIN-3 study results published. discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global. Phase 3 study in a biomarker-selected EGFR wild-type NSCLC patient. sensitivity to checkpoint inhibitors -- a significant unmet need. Cell Press journal Med 2025 and presented at SITC 2025. \"2025 was a year of important clinical and operational progress for BeyondSpring and SEED Therapeutics,\" said Dr. Lan Huang, Co-Founder, Chairman and Chief Executive Officer of BeyondSpring. \"We advanced our Phase 3 Plinabulin program, generated meaningful clinical data, and strengthened our strategic and financial position.\". \"BeyondSpring made meaningful progress advancing Plinabulin in Phase 3 NSCLC, while SEED Therapeutics reached a critical milestone -- initiating its first clinical trial following IND cle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4203","BK4139","BK4195","OS","HR","BK4097","BK4211","BK4225","BYSI","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621809037","title":"Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621809037","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621809037?lang=en_us&edition=fundamental","pubTime":"2026-03-24 11:32","pubTimestamp":1774323120,"startTime":"0","endTime":"0","summary":"Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer. SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positivetopline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin  in adult patients with advanced non-squamous non-small cell lung cancer .SAMSON-II is a randomized, double blind, parallel group, multicenter Phase 3 study conducted in 625 patients across 91 centers in 15 countries. Patients were randomized in a 1:1 ratio to receive HD204 or Avastin in combination with standard chemotherapy.\"These results illustrate the increasing precision with which biosimilarity can be established through advanced analytical and clinical PK studies,\" said Dr. Lisa Park, Chief Executive Officer of Prestige Biopharma. \"Our experience with HD204 supports the view that well-designed development programs can reliably anticipate cl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prestige-biopharma-announces-positive-topline-results-from-comparative-samson-ii-study-for-hd204-a-potential-biosimilar-to-avastin-bevacizumab-302722770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","PFS","BK4195","ORR","BK4181","BK7095","OS","BK4007","ORR.AU","BK4097","BK4218","PBH","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706487","title":"Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706487","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706487?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:45","pubTimestamp":1774269900,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Formal centralized and independent analysis of the clinical response data from the ACCENT trial has been undertaken and updated analysis provided to the CompanyThe data confirm that five (5","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260403/0/en/Amplia-Therapeutics-Reports-Four-Additional-Complete-Responses-and-Improved-Overall-Survival-Data-in-Accent-Pancreatic-Cancer-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4139","BK4195","PFS","PR","BK4211","BK4097","BK4539","INNMF","BK4161","ORR","LENZ","CR","BK4007","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621777299","title":"Press Release: Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777299","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621777299?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:00","pubTimestamp":1774263600,"startTime":"0","endTime":"0","summary":"Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing. Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA in 1L/2L+ R/M HNSCC on track for the second half of 2026. Announced appointment of Thomas Civik as Interim Chief Executive Officer. Expected cash runway into the fourth quarter of 2026. BOSTON, March 23, 2026  -- Pyxis Oncology, Inc. , a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today provided a business update, and reported financial results for the year and quarter ended December 31, 2025.-- Pyxis Oncology announced positive preliminary data for micvotabart. -- Monotherapy: 46% confirmed objective response rate  and 92%. disease control rate  observed with MICVO as monotherapy in. 2L+ R/M HNSCC . MICVO as monotherapy was. generally well tolera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","LU2487616109.SGD","ORR","R","BK4139","BK4022","BK4585","BK4588","L","PYXS","BK4107","LU0210528500.USD","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":134,"code":"91000000","status":"200"}]}}